[Translation] A randomized, open-label, single-dose, two-formulation, double-crossover controlled trial was conducted to evaluate the bioequivalence of a single oral dose of isosorbide mononitrate tablets in healthy Chinese subjects in the fasting and fed states.

主要目的：观察健康受试者空腹及餐后状态下单剂量口服受试制剂单硝酸异山梨酯片（规格：20mg，生产厂家：山东博瀚制药有限公司）后血药浓度的经时过程，估算相应的药代动力学参数；并以单硝酸异山梨酯片（商品名：Monoket®，规格：20mg，持证商：Merus Labs Luxco II, S.à.r.l.）为参比制剂，进行人体生物等效性正式试验，为该药注册申报和临床应用提供参考依据。次要目的：观察受试者空腹及餐后状态下口服受试制剂和参比制剂的安全性。

[Translation]

The primary objective was to observe the time course of plasma drug concentrations of the test formulation, isosorbide mononitrate tablets (20 mg, manufacturer: Shandong Bohan Pharmaceutical Co., Ltd.), in healthy volunteers after a single oral dose in the fasting and fed states, and to estimate the corresponding pharmacokinetic parameters. A formal bioequivalence study was conducted in humans using isosorbide mononitrate tablets (Monoket®, 20 mg, licensee: Merus Labs Luxco II, S.à.r.l.) as the reference formulation, to provide a reference for drug registration and clinical application. The secondary objective was to observe the safety of the test and reference formulations after oral administration in the fasting and fed states.

Start Date17 Dec 2025

Sponsor / Collaborator

Shandong Bohan Pharmaceutical Co., Ltd.

CTR20254354

/ CompletedNot Applicable

随机、开放、两制剂、交叉对照设计，评价中国健康受试者在空腹及餐后状态下单次单次口服受试制剂单硝酸异山梨酯缓释片后的生物等效性正式试验

[Translation] A randomized, open-label, two-dose, crossover controlled trial was conducted to evaluate the bioequivalence of a single oral dose of isosorbide mononitrate extended-release tablets in healthy Chinese subjects under fasting and postprandial conditions.

主要目的：以山东博瀚制药有限公司提供的单硝酸异山梨酯缓释片为受试制剂；并以Kern Pharma S.L.持证的单硝酸异山梨酯缓释片为参比制剂，进行人体相对生物利用度和生物等效性评价。

[Translation]

Main objective: To evaluate the relative bioavailability and bioequivalence of isosorbide mononitrate sustained-release tablets provided by Shandong Bohan Pharmaceutical Co., Ltd., as the test formulation, and isosorbide mononitrate sustained-release tablets certified by Kern Pharma S.L., as the reference formulation.

Start Date05 Dec 2025

Sponsor / Collaborator

Shandong Bohan Pharmaceutical Co., Ltd.

NCT07252544

/ Not yet recruitingPhase 3IIT

Isosorbide Mononitrate and Butylphthalide to Reduce the Risk of Disability in Patients With Acute Lacunar Stroke: a 2×2 Factorial Randomized Controlled Trial (IMPACT)

The goal of this multicenter, double-blind, 2×2 factorial randomized controlled trial is to evaluate the efficacy and safety of isosorbide mononitrate, butylphthalide, and their combination in reducing disability in patients with acute lacunar stroke.

Start Date01 Dec 2025

Sponsor / Collaborator

Beijing Tiantan Hospital

[+1]

100 Clinical Results associated with Isosorbide Mononitrate

100 Translational Medicine associated with Isosorbide Mononitrate

100 Patents (Medical) associated with Isosorbide Mononitrate

1,598

Literatures (Medical) associated with Isosorbide Mononitrate

31 Dec 2025·Journal of Maternal-Fetal & Neonatal Medicine

Statement of Retraction: Comparing vaginal misoprostol versus Foley catheter plus vaginal isosorbide mononitrate for labor induction

Article

15 Dec 2025·JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS

Comparing Fixation Techniques in Metacarpal Fractures: Intramedullary Screw Versus Open Reduction Internal Fixation With Plate and Screw Construct

Article

Author: Jodoin, Zachary N ; Lundquist, Kathleen F ; Rose, Ryan ; Bethiel, Jonathan ; McDonald, Casey D

Purpose::

The purpose of this study is to compare intramedullary headless screw (IMN) versus plate and screw fixation (open reduction internal fixation [ORIF]) in metacarpal (MC) fractures, specifically looking at implant cost, operating room time, outcomes, and complications. We hypothesize that IMN will provide at least equivalent outcomes and complication rates compared with ORIF while simultaneously decreasing operating room time and lowering overall costs.

Methods::

Patients with MC fractures treated surgically at a single, level-one, trauma center between January 2018 and December 2022 were identified. Eighty-five patients and 108 fractures were included. Records were retrospectively reviewed for demographic information, injury data, surgical details, and follow-up information.

Results::

The average age of included patients was 32.4 years. The leading causes of injury included altercations, falls, and motor vehicle collisions. Tourniquet time was an average of 79.9 minutes in the ORIF group and 37.6 minutes in the IMN group. Average cost of the implant and time to union were similar in both the groups. IMN fixation had faster time to motion and time to full range of motion. Complications, including revision surgery rates, wound infections, implant complications, and non/mal unions, were collected. Nine patients underwent revision surgery, eight in the ORIF group and one in the IMN group. Two superficial wound infections were noted in the ORIF group. One implant complication was observed in the ORIF group, as defined by implant breakage after the patient punched a wall. Three implant removals were noted, all in the ORIF group.

Conclusion::

In our experience, the use of an intramedullary screw for fixation of MC fractures is a reliable and safe method of fixation. The use of this procedure provides patients with quicker return to motion, faster time to full range of motion, and similar time to union with fewer complications. Furthermore, it resulted in decreased tourniquet time resulting in decreased overall cost.

Level of Evidence::

Retrospective review, Level III Therapeutic.

01 Dec 2025·Alzheimers & Dementia

Repurposed Drug Prioritisation Pipeline for an Alzheimer’s Disease Multi‐arm Platform Trial

Article

Author: Mursaleen, Leah ; Raymont, Vanessa ; O'Brien, John T ; Schneider, Lon S. S ; Karran, Eric H ; Iqbal, Sabahat ; Mummery, Catherine J. ; Rizzo, Laura ; Vandenberghe, Rik ; Olivares, Cristina Bonet ; Reeves, Suzanne J ; Wilcock, Gordon ; Dunne, Ross ; Cummings, Jeffrey L. ; Ducotterd, Fiona ; Parker, Thomas D ; Reith, Alastair ; Malhotra, Paresh ; Underwood, Benjamin R ; Carpenter, James ; Wong, Charis

Abstract:

Background:

Despite recent developments in amyloid‐clearing therapies for Alzheimer's Disease (AD), there remains a need for more effective, safe treatments. Funded by the UK National Institute of Health and Care Research, our aim was to establish a robust, systematic, and unbiased drug prioritisation pipeline to identify repurposed drugs with the greatest potential for sustained clinical effect in clinical 'real‐world' AD (MMSE >17). These would then be considered for inclusion in a planned multi‐arm UK platform trial.

Method:

We invited the wider AD community to propose compounds by summarising their rationale and evidence in a prespecified drug proposal form. Fourteen proposals were received, and the drug proposers were invited to the first panel meeting. They presented a pre‐clinical data focused rationale for each compound to an international expert panel comprised of AD clinicians, scientists, industry professionals, as well as both charity and patient/public representatives. In the context of a platform trial using prespecified primary outcome of cognition (ADAS‐Cog, with neuropsychiatric symptoms and everyday activities as secondary outcomes), the panel ranked their top three compounds based on efficacy, biological plausibility, and safety in AD. Ten compounds were taken forward with two subsequently excluded due to lack of data in humans. We compiled extended drug curriculum vitae (CV) for the eight shortlisted compounds. This incorporated practical clinically relevant information and was supplemented by systematic clinical literature review using Repurposing Living Systematic Review (ReLiSyR), a machine learning tool that searches databases and screens studies to identify relevant publications.

Result:

Drug CVs were reviewed in a second panel meeting. Compound rankings were repeated with previous considerations and also practical clinical factors. The highest ranked compounds were atomoxetine (1 st ), metformin (2 nd ), isosorbide mononitrate and levetiracetam (joint 3 rd ). The pivotal determining factors across the top ranked compounds included scientific evidence of plausible mechanistic pathways in AD as well as evidence of substantial clinical data on safety and tolerability.

Conclusion:

We present a practical approach to prioritising repurposed drugs to evaluate in the context of clinical AD. We would like to thank our patient and public contributors and the wider investigator team.

News (Medical) associated with Isosorbide Mononitrate

14 Aug 2025

·www.prnewswire.com

Navamedic ASA: Financial report for the 2nd quarter and first half of 2025

OSLO, Norway, Aug. 14, 2025 /PRNewswire/ -- In the first half of 2025, Navamedic ASA (OSE: NAVA), a Nordic pharma company and trusted supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies, delivered revenues of NOK 269.3 million, down from NOK 277.2 million in 2024. Excluding the milestone license fee from Orion corporation of NOK 22.7 million in 2024, revenues grew by 5.8 per cent YoY, gross margin improved to 37.3 per cent, compared to 37.0 per cent in Q2 2024 and EBITDA amounted to NOK 22.9 million compared to EBITDA of NOK 18.4 million in 2024. The performance was primarily driven by the Hospital area, particularly the antibiotics portfolio. Recent tender wins have driven sales growth for the antibiotics portfolio, which is up 48.4% YoY. "Having invested in various strategic growth initiatives over the last year, we are encouraged by the results in the second quarter of 2025. Excluding the Orion license fee last year, the 5.8 per cent revenue growth was positively impacted by Nordic tender wins for our antibiotics portfolio. Furthermore, several products, including Imdur® from our Prescription Drugs (RX) segment, have shown strong performance this quarter," said Kathrine Gamborg Andreassen, CEO of Navamedic. "We are also pleased to announce approval of the medical device OraFID® as primary package for Flexilev®, our medical treatment for Parkinson disease, enabling personalized, fine-tuned treatment with minitablets," she added. Business area update and Q2 key figures During the second quarter, the Hospital (up 23.5 per cent YoY) business area delivered strong growth. Prescription Drugs and Consumer Health were down 2.8 and 3.5 per cent YoY respectively in the period. As part of the Prescription Drugs (RX) area, revenues of Imdur® delivered strong revenues in the period and is up 101.0% YoY. Flexilev®, the company's unique treatment for Parkinson's disease, delivered sales growth of 4.8 per cent YoY. Mysimba® revenues were lower than last year by 12% YTD, while variable between the quarters (-26.6% YoY). For the Hospital area, recent tender wins drove sales growth in the antibiotics portfolio, which is up 48.4 per cent YoY, whilst the Medical Nutrition portfolio showed 3.3.% growth. The company's third business area, Consumer Health, delivered mixed results (-3.5%). Revenues of Modifast were slightly down (-1.1%), whilst Eroxon® saw a 10.7 per cent increase in revenues. Operating results (EBIT) for the second quarter of 2025 amounted to NOK 6.3 million, compared to NOK 6.2 million in 2024, excluding milestone license fee. Operating costs ended at NOK 41.1 million, compared to NOK 39.4 million last year. Net financial items ended at negative NOK 8.1 million and profit before tax was negative NOK 1.5 million. Outlook Navamedic continues to see growth and new expansion opportunities and reiterates its mid-term ambition of building a NOK 1 billion revenue company. "The past six months have been marked by execution across multiple fronts, from product and company acquisitions to successful launches and impactful marketing initiatives. Several initiatives, such as the dne pharma acquisition, will take time to translate into our growth results but with a solid foundation and continued operational progress, we are well-positioned to realize our ambition of reaching NOK 1 billion in revenue," Andreassen concluded. Presentation Navamedic will present the results for the second quarter of 2025 at 08.30 today. CEO Kathrine Gamborg Andreassen and CFO Lars Hjarrand will host the presentation, which will take place at Haakon VIIs gate 2 in Oslo. It will be webcast at the following link: Note: EBITDA and other alternative performance measures (APMs) are defined and reconciled to the IFRS financial statements as a part of the APM section in the attached presentation. For further information, please contact: Kathrine Gamborg Andreassen, CEO, Navamedic Mobile: +47 951 78 680 E-mail: [email protected] Lars Hjarrand, CFO, Navamedic Mobile: +47 917 62 842 E-mail: [email protected] About Navamedic Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's quality of life by being a reliable supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies. Our growing product portfolio has been carefully selected to meet current public health concerns, such as obesity, Parkinson's disease, antibiotics and metabolism, to empower people to live healthier and more fulfilling lives. What sets us apart is our deep-rooted commitment to understanding the needs and requirements of the countries where we are present. Our local insight and competence enable us to understand the specific needs of each country where we operate and ultimately to gain market access. This makes us a preferred partner for international companies expanding their footprint across the Nordics and Benelux regions, through either in-licensing or out-licensing. Navamedic has been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA) and is headquartered in Oslo, Norway. For more information, please visit Navamedic.com This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. This information was brought to you by Cision . The following files are available for download: WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

AcquisitionFinancial StatementDrug Approval

30 Apr 2025

·www.prnewswire.com

Navamedic Q1 2025: Strong start of the year and well-positioned for future growth

OSLO, Norway, April 30, 2025 /PRNewswire/ -- In the first quarter of 2025, Navamedic ASA (OSE: NAVA) , a Nordic pharma company and trusted supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies, reported revenues of NOK 132.0 million, representing a 9.2 per cent increase from the same period in 2024. EBITDA reached NOK 12.8 million, up from NOK 8.5 million last year. Gross margin improved to 40.7per cent, compared to 38.7per cent in Q1 2024. The strong performance was primarily driven by the Hospital area, particularly the antibiotics portfolio, supported by two long-term Nordic tenders secured in 2024. The company also experienced double-digit revenue growth in its Prescription Drugs (RX) area, contributing to the overall growth. "After investing in several strategic growth initiatives last year, we are pleased to see strong results already in the first quarter of 2025. The positive impact of the Nordic tender wins for our antibiotics portfolio has just begun to materialize. In addition, several products, including Mysimba® and Imdur® from our Prescription Drugs (RX) segment, delivered strong performance in the quarter," said Kathrine Gamborg Andreassen, CEO of Navamedic. "We are also pleased to announce the renewal of our agreement with TopRidge Pharma, securing the exclusive rights to market and sell Imdur® for another eight years. Over the past few years, we have systematically expanded and matured our product portfolio while investing in initiatives to drive future growth. The strong start to 2025 confirms the progress we are making," she added. Business area update and Q1 key figures During the first quarter, the Prescription Drugs (up 11.5 per cent YoY) and Hospital (up 15.2 per cent YoY) business areas delivered strong growth. Consumer Health had a steady development in the period (up 0.3 per cent YoY). As part of the Prescription Drugs area, revenues of Mysimba® increased by 7.3 per cent YoY. During the quarter, the European Medicines Agency's Human Medicines Committee also announced its review of Mysimba®. It affirmed that the benefits continue to outweigh the risks for weight management in adults with obesity or overweight. Imdur® and Nitrolingual® performed well in the quarter and were up 54 per cent and 22 per cent, respectively. Flexilev®, the company's unique treatment for Parkinson's Disease, delivered sales growth of 13 per cent YoY. Forlax® had a revenue decrease of 45 per cent due increased competition. For the Hospital area, the two tender wins drove sales growth in the antibiotics portfolio, which is up 32 per cent YoY, whilst the Medical Nutrition portfolio maintained steady sales. The company's third business area, Consumer Health, delivered stable results. Revenues of Modifast were steady during Q1, whilst Absolut Torr (up 49 per cent YoY) and ThermaCare (up 8 per cent YoY) experienced strong growth. Eroxon® saw a 9 per cent decrease in revenues, which is explained by a stock build-up in Q1 2024. Operating results (EBIT) for the first quarter of 2025 amounted to NOK 9.1 million, compared to NOK 4.9 million in 2024. Operating costs ended at NOK 40.9 million, compared to NOK 38.3 million last year. Net financial items ended at negative NOK 11 million and profit before tax was negative NOK 1.8 million. Outlook Navamedic continues to see strong growth and new expansion opportunities and reiterates its mid-term ambition of building a NOK 1 billion revenue company. "We have had a strong start to 2025. We have several key hero products across our three business areas, many of which have the potential to succeed internationally. Part of our work moving forward will be to identify growth opportunities for these products to support future growth," Andreassen concluded. Presentation Navamedic will present the results for the first quarter of 2025 at 08.30 today. CEO Kathrine Gamborg Andreassen and CFO Lars Hjarrand will host the presentation, which will take place at Haakon VIIs gate 2 in Oslo. It will be webcast at the following link: Note: EBITDA and other alternative performance measures (APMs) are defined and reconciled to the IFRS financial statements as a part of the APM section in the attached presentation. For further information, please contact: Kathrine Gamborg Andreassen, CEO, Navamedic Mobile: +47 951 78 680 E-mail: [email protected] Lars Hjarrand, CFO, Navamedic Mobile: +47 917 62 842 E-mail: [email protected] About Navamedic Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's quality of life by being a reliable supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies. Our growing product portfolio has been carefully selected to meet current public health concerns, such as obesity, Parkinson's disease, antibiotics and metabolism, to empower people to live healthier and more fulfilling lives. What sets us apart is our deep-rooted commitment to understanding the needs and requirements of the countries where we are present. Our local insight and competence enable us to understand the specific needs of each country where we operate and ultimately to gain market access. This makes us a preferred partner for international companies expanding their footprint across the Nordics and Benelux regions, through either in-licensing or out-licensing. Navamedic has been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA) and is headquartered in Oslo, Norway. For more information, please visit Navamedic.com. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. This information was brought to you by Cision The following files are available for download: WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Financial Statement

29 Apr 2025

·www.pharmaindustrial-india.com

Navamedic Extends Imdur Distribution Agreement Until 2032

Navamedic ASA has signed a renewed distribution agreement with TopRidge Pharma Limited (TopRidge) for Imdur®, valid until June 2032, including options for new products to be added to the agreement. "It is a pleasure to announce that we have agreed with our great partner TopRidge Pharma, to revise and renew the distribution agreement for Imdur until 2032. Imdur is our second largest single brand and is currently marketed by us in the Nordics, the Netherlands, the Baltics, Greece and Cyprus. Although there is generic competition in this field, the original product is highly valued by the patients who often stay on the treatment for a long period of time," said Kathrine Gamborg Andreassen, Chief Executive Officer of Navamedic. Imdur® (isosorbide mononitrate), is a prescription medication used to prevent angina pectoris due to heart disease. It was first launched in Europe in 1985. Navamedic commenced distribution of the product as part of a strategic partnership and long-term distribution agreement with TopRidge Pharma Limited in 2016. "Imdur® remains an important product to Navamedic, and we appreciate the efforts made by TopRidge to update the Marketing Authorisations and to secure steady supplies to our markets. With the renewal of this agreement, we look forward to exploring further collaboration opportunities for additional products in the future," added Gamborg Andreassen.

Drug ApprovalLicense out/in

100 Deals associated with Isosorbide Mononitrate

External Link

KEGG	Wiki	ATC	Drug Bank
D00630	Isosorbide Mononitrate	C01DA14	DB01020

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Heart Failure	China	Livzon Group Livzon Pharmaceutical Factory	01 Jan 1993
Angina Pectoris	United States	Promius Pharma LLC	30 Dec 1991

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Angina, Stable	Phase 3	Brazil	Laboratórios Baldacci SA	01 Jul 2014
Myocardial Infarction	Phase 1	China	-	10 Oct 2013
Vasospasm	Phase 1	China	-	10 Oct 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03451591 (LACI-2, CTgov)	Phase 2/3	Stroke, Lacunar	363	Isosorbide Mononitrate (Isosorbide Mononitrate XL (ISMN))	zydfdzjquh = vabkeovega bcjtzxeihe (uxstvgrugt, fuxfjrtavs - zjvrvzubfx) View more	-	12 Nov 2024
				Cilostazol (Cilostazol)	zydfdzjquh = taimorxacr bcjtzxeihe (uxstvgrugt, fgazbckxjo - apxcjzkoms) View more
NCT04310995 (ASRAB-pilot, ESC2024)	Phase 4	complication of coronary artery bypass graft	150	Nicorandil 15 mg daily	tockpazydk(hmjaqclxbg) = hvrkipmpnb wipfupbozx (qbttljfonr ) View more	Negative	30 Aug 2024
				Isosorbide mononitrate 50 mg daily	tockpazydk(hmjaqclxbg) = nzmypyogca wipfupbozx (qbttljfonr ) View more
NCT04051957 (CTgov)	Phase 2	Kidney Diseases \| Proteinuria \| Hypertension	9	Isosorbide Mononitrate (Isosorbide Mononitrate)	eqcjfftatp = eztkqzqcei hscnctqllg (ogbbhepebf, cidbavrccy - xhhethhavs) View more	-	03 Aug 2022
				Placebo oral tablet (Placebo)	eqcjfftatp = yppqctlhjj hscnctqllg (ogbbhepebf, rjvdcmchwn - ykpaswpqbo) View more
NCT03171480 (NOPE, CTgov)	Phase 4	Obstetric Labor, Premature \| Pre-Eclampsia	176	Monoket Pill (Monoket Pill)	atwjiyhyhq = klaurtwybs wieufmyylk (duijiyimwo, otcvppunpj - rbmwikdssa) View more	-	04 Jan 2022
				Placebo (Placebo Pill)	vffxqddhls = unyllwmtdd uzibpjbtwv (dpbyrgfwyg, ejgqrthktq - gfurgjloxd) View more
NCT03171480 (Pubmed \| Am J Obstet Gynecol MFM)	Phase 4	Hypertension	176	Vaginal Isosorbide Mononitrate	ftjlkqfpxr(nnzrxvewwd) = vjzczoopsf akodciwsal (zhcgrlsdqw ) View more	Negative	27 Feb 2021
				Placebo	ftjlkqfpxr(nnzrxvewwd) = mjrxzouyih akodciwsal (zhcgrlsdqw ) View more
NCT02791906 (CTgov)	Phase 2	Chronic Kidney Diseases	8	ISMN (ISMN Only)	zvuhyfpfwy(obefsxhayt) = vsgmlxagun femzcoywks (nwjdygltkq, 31.5) View more	-	13 Aug 2020
				Vitamin C+ISMN (ISMN AND Vitamin C)	zvuhyfpfwy(obefsxhayt) = etvtgfqxwx femzcoywks (nwjdygltkq, 1.26) View more
NCT02053493 (NEAT-HFpeF, CTgov)	Phase 2	Heart Failure	110	Placebo+Isosorbide Mononitrate (Isosorbide Mononitrate Crossover to Placebo)	diltsoauph(rrgqqjlajf) = oadyljhbra aaaixejrpr (zjendwpkcq, 4601) View more	-	28 Nov 2016
				Placebo+Isosorbide Mononitrate (Placebo Crossover to Isosorbide Mononitrate)	diltsoauph(rrgqqjlajf) = ahdypagotf aaaixejrpr (zjendwpkcq, 6286) View more
NCT02053493 (Pubmed \| Br Dent J \| N Engl J Med) Manual	Phase 2	Heart Failure	110	Isosorbide Mononitrate	sfygdqhvzj(hvjottssdu) = hepotzvuvn havfrpbwhl (hriibmkxlp, -780 to 17) View more	Negative	10 Dec 2015
				Placebo	-
NCT01430780 (Pubmed \| Coron Artery Dis)	Not Applicable	Coronary Artery Disease	60	ISMN 20 mg retarded release	wtbyqcbjsc(cjtztmtxhq) = lwscyruqeh jjwhzqwqgn (myxprfmmdm )	Negative	01 Nov 2013
				Placebo	wtbyqcbjsc(cjtztmtxhq) = sllwczpqwj jjwhzqwqgn (myxprfmmdm )
NCT01130168 (0000-166, CTgov)	Phase 1	Hypertension	38	Isosorbide mononitrate extended release (ISMN ER) (ISMN ER)	iyrbrhwgkr(aqohhrnldv) = hqdyexevwh jglitmbpzl (ikxibskydz, 4.5) View more	-	28 May 2012
				Amlodipine (Amlodipine)	iyrbrhwgkr(aqohhrnldv) = oprpofwrdt jglitmbpzl (ikxibskydz, 4.5) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis